Search

Displaying results 2431 - 2440 of 10000 in total
  1. Drug

    Iobenguane

    go.drugbank.com/drugs/DB06704
    ApprovedInvestigational

    Iodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [A189195] The development of oral gepants, including ubrogepant, may therefore constitute a significant advance in migraine headache treatment and may become the new standard of therapy in the treatment … remain in clinical development.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  3. Drug

    Paltusotine

    go.drugbank.com/drugs/DB16277
    ApprovedInvestigational

    [A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061] … Paltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth

  4. Drug

    Chloroprocaine

    go.drugbank.com/drugs/DB01161
    ApprovedInvestigational

    [A252952] Chloroprocaine can be given as an injection, and is available in formulations with and without methylparaben as a preservative. … Chloroprocaine is an ester local anesthetic commonly available in its salt form, chloroprocaine hydrochloride.

  5. Drug

    Amlexanox

    go.drugbank.com/drugs/DB01025
    ApprovedWithdrawn

    Amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers. … Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis.

    International brands: OraDisc A
  6. Drug

    Conivaptan

    go.drugbank.com/drugs/DB00872
    Approved

    Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). … It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: Vaprisol Dextrose In Plastic Container
  7. Drug

    Iloperidone

    go.drugbank.com/drugs/DB04946
    ApprovedInvestigational

    Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009. … [A3024] It is considered to be a second-generation antipsychotic drug [A263552] with multiple receptor binding profile, although it shows high affinity towards 5-HT<sub>2A</sub> and dopamine D2 receptors

  8. Drug

    Buserelin

    go.drugbank.com/drugs/DB06719
    ApprovedInvestigational

    It is used in prostate cancer treatment. … Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR).

  9. Drug

    Inotersen

    go.drugbank.com/drugs/DB14713
    ApprovedInvestigational

    Inotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. … It was FDA approved in October 2018.

  10. Drug

    Alcloxa

    go.drugbank.com/drugs/DB11205
    Approved

    Mixtures: Watkins Roll On Deodorant